Epigenetic reprogramming by CBP/P300 bromodomain inhibition of triple-negative breast cancer and the immune microenvironment

被引：0
|
作者：
Yuan, Xueying
Soth, Michael
Zhao, Na
Jones, Philip
Rosen, Jeffrey
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 03期
关键词：
D O I：
10.1158/1538-7445.ADVBC23-B047
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B047
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Reprogramming epithelial-mesenchymal transition and the immune microenvironment in triple-negative breast cancer with epigenetic drugs.
    Yuan, Xueying
    Soth, Michael
    Jones, Philip
    Rosen, Jeffrey
    CANCER RESEARCH, 2022, 82 (23)
  • [2] CREB-binding protein/P300 bromodomain inhibition reduces neutrophil accumulation and activates antitumor immunity in triple-negative breast cancer
    Yuan, Xueying
    Hao, Xiaoxin
    Chan, Hilda L.
    Zhao, Na
    Pedroza, Diego A.
    Liu, Fengshuo
    Le, Kang
    Smith, Alex J.
    Calderon, Sebastian J.
    Lieu, Nadia
    Soth, Michael J.
    Jones, Philip
    Zhang, Xiang H. F.
    Rosen, Jeffrey M.
    JCI INSIGHT, 2024, 9 (20)
  • [3] Using epigenetic reprogramming to target triple-negative breast cancer
    Sharma, D.
    Knight, B. B.
    Yacoub, R.
    Liu, T.
    Taliaferro-Smith, L.
    Nagalingam, A.
    O'Regan, R. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] Distinct modulation of IFNγ-induced transcription by BET bromodomain and catalytic P300/CBP inhibition in breast cancer
    Hogg, Simon J.
    Motorna, Olga
    Kearney, Conor J.
    Derrick, Emily B.
    House, Imran G.
    Todorovski, Izabela
    Kelly, Madison J.
    Zethoven, Magnus
    Bromberg, Kenneth D.
    Lai, Albert
    Beavis, Paul A.
    Shortt, Jake
    Johnstone, Ricky W.
    Vervoort, Stephin J.
    CLINICAL EPIGENETICS, 2022, 14 (01)
  • [5] Targeting cancer with selective cbp/p300 bromodomain inhibitors
    Jaleel, Mahaboobi
    Senaiar, Ramesh S.
    Abbineni, Chandrasekhar
    Renukappa, Girish A.
    Mukherjee, Subhendu
    Marappan, Sivapriya
    Samiulla, D. S.
    Aravind, A. B.
    Kumar, Naveen R.
    Reddy, Venkata Siva N.
    Babu, Asha
    Srinivas, Akhila P.
    Yadlapalli, Prasad
    Tgore, Suraj
    Raghavendra, N. R.
    Naik, Chandranath D.
    Giri, Sanjeev
    Antony, Thomas
    Nellore, Kavitha
    Chelur, Shekar
    Daginakatte, Girish
    Ravanti, laura
    Myllymaki, Mikko
    Wohlfahrt, Gerd
    Mattila, Elina
    Karlsson, Stefan
    Bjorkman, Mari
    Riikonen, Reetta
    Ikonen, Tarja
    Leimu, Laura
    Malmstrom, Chira
    Korjamo, Timo
    Moilanen, Anu
    Ramachandra, Murali
    Samajdar, Susanta
    CANCER RESEARCH, 2020, 80 (16)
  • [6] Distinct modulation of IFNγ-induced transcription by BET bromodomain and catalytic P300/CBP inhibition in breast cancer
    Simon J. Hogg
    Olga Motorna
    Conor J. Kearney
    Emily B. Derrick
    Imran G. House
    Izabela Todorovski
    Madison J. Kelly
    Magnus Zethoven
    Kenneth D. Bromberg
    Albert Lai
    Paul A. Beavis
    Jake Shortt
    Ricky W. Johnstone
    Stephin J. Vervoort
    Clinical Epigenetics, 2022, 14
  • [7] BRCAness Phenotype and Immune Microenvironment in Triple-Negative Breast Cancer
    Ramos Navas, Luisa Ayelen
    Esquivel Vazquez, Beatriz
    Salido Ruiz, Eduardo
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2024, 32 : 932 - 933
  • [8] Targeting p300 for inhibiting triple negative breast cancer
    Liao, Daiqing
    Yang, Heng
    Luo, Jian
    CANCER RESEARCH, 2012, 72
  • [9] The role of metabolic reprogramming in immune escape of triple-negative breast cancer
    Bao, Ruochen
    Qu, Hongtao
    Li, Baifeng
    Cheng, Kai
    Miao, Yandong
    Wang, Jiangtao
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [10] BET Bromodomain Inhibitors in Triple-Negative Breast Cancer
    不详
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 (04) : 343 - 343
12345